PFM
ACAD icon

Privium Fund Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Privium Fund Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-70,400
Closed -$1.5M – 59
2025
Q3 		$1.5M Sell
70,400
-78,000
-53% -$1.84M 0.27% 34
2025
Q2 		$3.17M Hold
148,400
– – 0.68% 19
2025
Q1 		$2.46M Hold
148,400
– – 0.64% 22
2024
Q4 		$2.72M Hold
148,400
– – 0.62% 25
2024
Q3 		$2.28M Hold
148,400
– – 0.57% 29
2024
Q2 		$2.35M Hold
148,400
– – 0.6% 31
2024
Q1 		$2.74M Buy
+148,400
New +$3.68M 0.73% 31

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Privium Fund Management's ACAD Position: Q4 2025 in Review

Privium Fund Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2025, closing a stake of 70,400 shares — an estimated $1.5M sold.

Privium Fund Management first reported a position in ACAD in Q1 2024 and held it in 7 quarters. The position peaked at $3.17M in Q2 2025. 336 funds tracked by Wall St. Rank hold ACAD as of Q4 2025.

  • Privium Fund Management reported no remaining Acadia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Privium Fund Management sold 70,400 Acadia Pharmaceuticals shares in Q4 2025, an estimated $1.5M.
  • Privium Fund Management first reported a position in Acadia Pharmaceuticals in Q1 2024 and held it in 7 quarters.
  • Privium Fund Management's Acadia Pharmaceuticals position peaked at $3.17M in Q2 2025.
  • 336 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2025.

Based on Privium Fund Management's 13F filing for Q4 2025, filed 3 Feb 2026.